Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open label study designed to evaluate the efficacy and safety of
neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA-N2
non-small cell lung cancer.